FDA-approved HDAC inhibitors such as vorinostat, romidepsin, panobinostat, and belinostat are approved for the treatment of certain cancers such as T cell lymphoma and multiple myeloma [129,130]. The gene discussed is HDAC9; the disease is cancer.